Continuity in Care: BD Taps Insider to Lead Peripheral Intervention Unit

FRANKLIN LAKES, N.J. – November 04, 2026 — In the rapidly evolving landscape of medical technology, the tools we use to navigate the human body are only as effective as the leadership guiding their development. Today, BD (Becton, Dickinson and Company) announced a significant leadership transition that underscores the value of institutional memory in a high-stakes industry. Effective November 16, company veteran Bridget Bagnato will step into the role of worldwide president of BD’s Peripheral Intervention business unit.

Based at the division's headquarters in Tempe, Arizona, Bagnato will oversee the global strategic, operational, and commercial performance of a portfolio deeply embedded in the treatment of peripheral vascular disease, oncology, and end-stage kidney disease. She will report directly to Peter Menziuso, executive vice president and president of the Interventional segment.

The appointment arrives at a critical juncture for the global medical technology giant. As healthcare systems worldwide grapple with aging populations and the rising prevalence of chronic conditions, the demand for minimally invasive, life-altering interventions has never been higher. By elevating a leader with more than 27 years of internal experience, the corporation is sending a clear message: in the race to innovate, understanding the intricate, human-centered realities of clinical care is just as vital as technological disruption.

The Value of Institutional Memory

In an era where executive hopping is commonplace, a nearly three-decade tenure at a single organization is a rarity. Bagnato's ascent through the ranks of the New Jersey-based company provides a fascinating case study in corporate continuity.

Most recently serving as worldwide president of the Specimen Management business unit, Bagnato has navigated the complex, highly regulated environment of pre-analytical solutions—a foundational element of modern diagnostics. Her prior leadership roles spanned Medication Delivery Solutions and the Surgery division, where she served as vice president and general manager of Surgical Complication Solutions.

This diverse trajectory means Bagnato brings a panoramic view of the healthcare continuum to her new role. From the precise demands of laboratory diagnostics to the high-pressure environment of the operating room, she has spent decades analyzing how medical devices intersect with human workflows.

"Bridget brings deep experience across BD and a strong understanding of our customers, with a proven ability to grow businesses through innovation and operational excellence," Menziuso stated in the official announcement. "I'm confident she will build on Peripheral Intervention's strong foundation, advancing differentiated technologies across peripheral vascular disease, oncology, and end-stage kidney disease to address significant unmet needs and deliver greater value for customers and patients."

Armed with a bachelor's degree from Villanova University and an MBA from Duke University's Fuqua School of Business, Bagnato is now tasked with translating that institutional knowledge into aggressive market expansion. Industry observers note that tapping an insider for this specific unit minimizes transition friction, allowing the company to maintain momentum in its vital research and development pipelines without the strategic whiplash that often accompanies external hires.

Navigating a Fiercely Competitive Landscape

The Peripheral Intervention unit operates within BD's broader Interventional segment, a critical growth engine that generated $4.505 billion in revenue in fiscal year 2023. Bagnato is inheriting a robust portfolio, but she is also stepping into a fiercely competitive arena.

In the peripheral vascular disease space, the company goes head-to-head with industry titans like Boston Scientific, Medtronic, and Cook Medical. The battleground is defined by continuous innovation in drug-coated balloons, advanced atherectomy devices, and complex stenting solutions. As clinicians increasingly prioritize limb salvage in patients with critical limb ischemia and seek better long-term patency rates for revascularization, the pressure to deliver clinical evidence alongside technological advancement is immense.

"The peripheral vascular market is unforgiving; it demands not just novel devices, but rigorous, long-term data proving that these interventions keep arteries open and keep patients out of the hospital," noted one veteran medical device analyst who monitors the sector. "Bringing in a leader who already understands the company's global supply chain and regulatory apparatus gives them a distinct tactical advantage in deploying these technologies rapidly."

Bagnato will need to leverage her operational expertise to differentiate the Tempe-based unit's offerings. This means not only pushing the boundaries of device engineering but also ensuring that these tools integrate seamlessly into the shifting economic realities of modern healthcare, where value-based care models heavily penalize readmissions and complications.

The Human Impact of Market Expansion

Beyond the boardroom strategies and market share battles lies the profound human element of peripheral interventions. The technologies Bagnato will now champion are not mere commodities; they are the literal lifelines for millions of patients navigating devastating diagnoses.

In interventional oncology, a field experiencing explosive growth, the focus is shifting toward minimally invasive, image-guided procedures. Bagnato will oversee a portfolio that includes biopsy needles, radiofrequency ablation systems, and chemotherapy port access. These tools represent a paradigm shift in cancer care, offering patients less traumatic alternatives to traditional surgery and integrating seamlessly with systemic therapies like immunotherapy. The goal is to transform cancer from a terminal diagnosis into a manageable chronic condition, preserving the patient's quality of life.

Similarly, in the realm of end-stage kidney disease, the interventions managed by this unit are critical for survival. Patients reliant on hemodialysis require durable vascular access. Products designed for the creation and maintenance of arteriovenous fistulas are essential to prevent the thrombosis and stenosis that can turn routine dialysis into a life-threatening crisis.

By applying a people-first philosophy to these product lines, leadership can ensure that research and development remain tethered to the actual lived experiences of patients and the clinicians treating them. Bagnato’s background in Surgical Complication Solutions—a field dedicated entirely to preventing negative patient outcomes—suggests a leadership style inherently attuned to patient safety and clinical efficacy.

Looking Ahead: Strategy and Execution

As Bagnato prepares to assume her new responsibilities on November 16, the road ahead is defined by both immense opportunity and stringent regulatory demands. The reimbursement landscape, largely dictated by entities like the Centers for Medicare and Medicaid Services, is in a state of constant flux. Securing favorable coverage for new, complex peripheral interventions requires unassailable clinical utility and proven cost-effectiveness.

Furthermore, the integration of digital health and real-time imaging into interventional procedures is reshaping the operating theater. The future of peripheral intervention lies not just in the physical devices, but in the data and software that guide their deployment.

Bagnato's mandate will be to synthesize these disparate elements—technological innovation, rigorous clinical evidence, shifting reimbursement models, and fierce competition—into a cohesive global strategy. Her 27-year history with the organization suggests she has the navigational charts required for the journey. As she takes the helm in Arizona, the broader medical community will be watching closely to see how this seasoned insider steers one of the most clinically vital divisions in the medical technology sector toward its next chapter of human-centered innovation.